G-CSF or GM-CSF can hasten myeloid engraftment post MA AlloSCT. GM-CSF is an earlier and broader acting CSF, which also induces more TH1. DC1 immune subsets preferentially compared to G-CSF. The objective of this study is to evaluate efficacy/safety of sequential administration of GM-CSF followed by G-CSF in children s/p MA AlloSCT. From 1/01-6/05 we enrolled 34 children: mean age 7.2 yrs; wt 32.3 kg; M:F ϭ 19:15; poor:average risk ϭ 13:21, TBI vs non-TBI based conditioning ϭ 12:22; MFD vs umbilical cord blood (UCB) ϭ 12:22. Indications for AlloSCT included malignant (MDS, ALL, AML, APL, NHL [n ϭ 22]) and non-malignant (SAA, HLH, SCD, B-thal [n ϭ 12]) disorders. GM-CSF (250 g/m 2 IV QD) was initiated on day 0 post stem cell infusion. GM-CSF was switched to G-CSF (10 g/kg IV QD) when WBC Ն300/ mm 3 ϫ 2 days. G-CSF was continued until ANC Ն2500/mm 3 ϫ 2 days, then tapered to maintain ANC Ն1000/mm 3 . GVHD prophylaxis: tacrolimus (target 5-20 ng/mL) and mycophenolate as previously described (Osunkwo/Cairo, BBMT 2004) . All pts were prophylaxed against PCP, HSV, CMV, and fungal infections. There were no statistically significant differences in baseline characteristics between MFD vs UCB groups. Mean CD34 ϩ cell dose/kg ϭ 36.3 ϫ 10 5 and TNC dose/kg ϭ 39.3 ϫ 10 7 . Median time to WBC Ն300/mm 3 ϭ 15.5 d (10 vs 19.5 d MFD vs UCB). Median time of switch from GM-CSF (WBC Ն300/mm 3 ) to G-CSF and myeloid engraftment (ANC Ն500/ mm 3 ϫ 2 d) was 0.5 d (1.5 vs 3.5 d MFD vs UCB). Median time to myeloid and platelet engraftment (untransfused count Ն20000/mm 3 ϫ 7 d) were 17 d (13 vs 23.5 d MFD vs UCB) and 28 d (19 vs 33.5 d MFD vs UCB). Kaplan-Meier probability of 1 year OS was 67.2% (CI: 50.3-84.1). Adverse events attributable to G-CSF (n ϭ 1) or GM-CSF (n ϭ 3) were: bone pain, pleural and pericardial effusions. Of these, 3/4 pts received concomitant oprelvekin (IL-11). Infections occurring prior to day ϩ60 included 21 (62%) pts with CVL bacteremia (coagulase (Ϫ) staphylococci [n ϭ 9], gram (Ϫ) bacilli [n ϭ 10]) and 2 (6%) pts with invasive fungal infections. This pilot study demonstrated safety and efficacy of sequential GM-CSF/G-CSF administration in pediatric AlloSCT recipients. Myeloid recovery after WBC Ն300/mm 3 on GM-CSF only took 1-3 days after switch to G-CSF. Platelet engraftment following UCBT appears more rapid with sequential GM-CSF/G-CSF compared to historical controls. Sequential GM-CSF/G-CSF may be more cost-effective than G-CSF alone (cost-saving of $1402/patient based on 2004 Red Book AWP). Oliveira, M.M., Bonfim, C., Bitencourt, M., Funke, V., Setubal, D., Ruiz, J., Medeiros, C.R., Zanis-Neto, J., Pasquini, R. Federal University of Parana, Curitiba, PR, Brazil. PNH is a clonal disorder caused by acquired mutations of the PIG-A gene. Many pts achieve long term survival if adverse factors are not present. SCT can be curative for young pts with severe pancytopenia, massive hemolysis, thrombotic complications or leukemic transformation. SCT complications are frequent reported due to an increased risk of graft failure and transplant related mortality. In this study we retrospectively analyze 15 pts with PNH submitted to SCT in our BMT center. Period: 03/88-02/05. Indication for SCT: severe pancytopenia: 12 pts, thrombosis: 2 pts and hemolysis: 1 pt. Age: 14-42 y (M: 29 y). Gender: 6F/9M. Time from diagnosis to SCT ranged from 2 to 133 months (M: 29.5 mo). Previous blood transfusions: 25 UI (range: 8-200 UI). Total nucleated cell infused: 1.72-4.56 ϫ 10 8 /kg (median: 2.7). Donor type: HLA identical siblings: 14 pts, unrelated identical donor: 1 pt. Stem cell source: bone marrow: 14 pts; peripheral blood: 1 pt. Preparatory regimen: busulfan (BU) 12 mg/kg ϩ cyclophosphamide (CY) 120 mg/kg: 11 pts (1 pt received BU 16 mg/kg), BU 8 mg/kg ϩ fludarabine 125 mg/m 2 : 2 pts; CY 120 mg/kg ϩ TBI ϩATG: 1 pt and CY 200 mg/kg: 1 pt. GVHD prophylaxis: methotrexate ϩ cyclosporine: 12 pts; others: 3 pts. Eleven pts are alive without evidence of PNH with a median follow-up of 1691 days (range: 125-5998 days). Estimated 5 year survival: 73%. Two pts died before day ϩ28 and were not evaluable for engraftment. 13 pts engrafted and the median time to reach ANC Ͼ500/l was 19 days (range: 14-25). Mucositis grade III-IV occurred in 7 pts. Two patients developed grade III-IV acute GVHD. One pt had progressive extensive chronic GVHD and another one had de novo extensive C-GVHD. No pt developed veno-occlusive disease. Four pts (median age of 36.5 yr) died on day ϩ10, ϩ11, ϩ71 and ϩ330 after SCT. Causes of death included infection (2 pts) and GVHD (2 pts).We conclude that pts with PNH and life threatening complications can achieve long term survival after SCT when HLA identical donors are used. In this group of patents we did not observe significant transplant related complications. Objectives: Non-Hodgkin's lymphoma (NHL) is one of the major indications for haematopoietic stem cell transplantation (HSCT). For chemo-sensitive relapsed cases, autologous HSCT is often the treatment of choice. Relapsed cases after autologous HSCT as well as those with extensive disease generally have poor prognosis and allogeneic HSCT becomes the only option for a cure. We summarized our experience in Queen Mary Hospital regarding the outcome of allogeneic HSCT for this disease. Methods: Hospital records of allogeneic HSCT for underlying NHL in the past fourteen years were retrieved. Clinical data were summarized according to the pre-HSCT characteristics, disease relapse and transplant-related mortality. Event-free (defined as either disease relapse or death after HSCT) and overall survival were evaluated by Kaplan-Meier analysis. Results: Since 1991, a total of 48 NHL patients (M:F 25:23) have undergone allogeneic HSCT. The median age was 42 (range: 23-63 years). Histological diagnoses were obtained from 40 patients and they comprised both B-cell (Burkitt or Burkitt-like ϭ 5, diffuse large B-cells ϭ 19, follicular ϭ 3, maltoma ϭ 1, Mantle cell ϭ 3) or T-cell lymphoma (angioimmunoblastic T-cell ϭ 3, T-lymphoblastic ϭ 4, peripheral T-cell ϭ 2). Allogeneic HSCT was performed mostly as salvage therapy for chemosensitive relapses after chemotherapy and autologous HSCT. Source of HSCT included HLA-matched siblings (n ϭ 41), matched unrelated donors (n ϭ 6) and parents (n ϭ 1). Forty-five patients received myeloablative and 3 received reduced intensity conditioning. The median EFS and OS were 38 and 40 months and at 160 months, the EFS and OS were 47% and 50%. When patients with diffuse large B-cell lymphoma were separately analyzed, the EFS and OS at 40 months were about 52% and none of the patients had disease relapse or mortality thereafter. Conclusion: We demonstrated that allogeneic HSCT may offer a cure for high risk NHL patients. Our results compared favorably with those reported in the literature. Cord blood banks (CBB) are required to monitor clinical outcomes of cord blood unit (CBU) transplants performed by transplant centers (TC). Obtaining accurate and timely follow-up data on clinical outcomes from the TC can be very difficult. The National Marrow Donor Program (NMDP), by virtue of their comprehensive activities with member network centers, collects outcomes data on recipients transplanted with either cord blood or adult donor cells. NMDP member transplant centers are required to submit data at defined intervals as part of their participation agreement. A system is in place to monitor compliance that includes a due process procedure for non-compliant centers. Recipients sign an IRB-approved consent form for data submission to the NMDP. All submitted data are verified through system checks at time of data entry. Identified errors are subject to a formal error correction process. Transplant centers are audited on a four year cycle to assure the accuracy and integrity of the data provided. At any given time, Ͼ90% of NMDP centers are compliant with forms submission requirements. The data elements include information on the results of the thaw, infusion related reactions, preparative regimens, neutrophil and platelet engraftment, GVHD, relapse, survival and death. Member cord blood banks receive a quarterly report from the NMDP which includes comprehensive data on the individual recipients for which their CBUs were used. The data include recipient demographics, infused cell dose, degree of HLA match, engraftment, GVHD, relapse, survival, and cause of death. While outcomes data are reported quarterly to member banks, thaw data are reported and reviewed on a continuous basis. TNC recoveries that are low (Ͻ60%) or high (Ͼ100%) are reviewed by NMDP staff to detect problems with CBU potency that might be linked to a certain bank, shipping procedure or thawing protocol at a TC. Future directions include trending analysis reports and review with the NMDP Quality Standards subcommittee. The NMDP's process for reporting quality assurance data to member banks is a valuable service that is unlikely to be feasible in a single bank. Morgan, L. 1 , Struck, R. 2 , Rodgers, A. 3 , Jursic, B. 4 , Waud, W. 3 , Papagiannis, C. 5 , Gale, R.P. 6 1. Inc., New Orleans, LA; 2. Cancer Medica, LLC, Birmingham, AL; 3. Southern Research Institute, Birmingham, AL; 4. Chemistry Department, University of New Orleans, LA; 5. MPI Research, Mattawan, MI; 6. ZIOPHARM Oncology, Charlestown, MA. Alkylators are widely used in conditioning regimens for bone marrow transplants. IPM is a bi-functional alkylator with crosslinking through G:C base sequences resulting in irreparable interstrand DNA cross-linking producing cell death. IPM alkylates DNA as a phosphorodiamidate and may cross-link DNA differently from phosphoramide mustard (PM) the major DNA-cross-linking moiety of cyclophosphamide (CPA). IPM is active in diverse cancer models but its chemical instability precluded pharmaceutical development; CPA and ifosfamide (IFOS) were developed as alternatives. We stabilized IPM with lysine (IPM-L; ZIO-201) and tested it in preclinical sub-acute pharmacology and toxicology models and in mice with human cancer xenografts. ZIO-201 and IPM were given IV daily ϫ 3 d. ZIO-201 sub-acute LD 10/50 in adult mice was 133 and 220 mg/kg (combined sexes) compared to 119 and 149 mg/kg for IPM. Bone marrow failure was the dose-limiting toxicity (DLT) of both drugs. In the MX-1 human breast cancer model, ZIO-201 was better than IPM: MTD: 93 vs. 40 mg/kg/dose and tumor versus control life extension (T-C): 10.2 versus 2.1 d. Because and ifosfamide [IFOS]) is not metabolized to acrolein or acetaldehydes, there was no kidney, bladder or CNS toxicity. ZIO-201 is in phase-1 trials in humans: data will be presented. Using ZIO-201 may increase the safety and efficacy of this class of alkylators in clinical settings where high-dose CPA and IFOS are used, like bone marrow transplants. Possible dose increases and activity in CPA-and IFOS-resistant cancers may broaden the target range. Supported by grant R44 CA83552 from the NCI/ SBIR program.
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR THE TREAT-MENT OF 15 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLO-BINURIA (PNH) IN BRAZIL

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN'S LYMPHOMA IN QUEEN MARY HOSPITAL-A SINGLE CENTRE EXPERIENCE
ISOPHOSPHORAMIDE MUSTARD-LYSINE (IPM-L; ZIO-201): A NEW AL-KYLATOR FOR BONE MARROW TRANSPLANTS
ADOPTIVE IMMUNOTHERAPY WITH TUMOR-DERIVED DONOR LYM-PHOCYTES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-PLANTATION
Hardy, N.M. 1 , Fellowes, V. 1 , Mariotti, J. 1 , Carter, C. 2 , June, C. 3 , Levine, B. 3 , Hakim, F. 1 , Vonderheide, R. 3 , Gress, R. 1 , Read, E.J. 2 , Fowler, D. 1 , Bishop, M.R. 1 1. National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; 2. Clinical Center, NIH, Bethesda, MD; 3. University of Pennsylvania, Philadelphia, PA. Treatment of refractory or recurrent malignancy with donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (alloHSCT) is limited in efficacy, and graft-vstumor (GVT) is often accompanied by graft-versus-host disease (GVHD). After alloHSCT, lymphocytes infiltrating residual tumor are likely of donor origin. Compared with DLI, they may provide enhanced antigen specificity and maintain tumor-specific homing, thus generate better GVT with less GVHD. We are testing this hypothesis through administration of ex-vivo activated tumor-derived lymphocytes (TDL) after alloHSCT. Clinical evaluation of TDL therapy was initiated with a 51 year-old woman for metastatic breast cancer whose disease progressed after matchedsibling alloHSCT and subsequent conventional therapy plus DLI. Metastases were surgically removed two weeks after administration of unmanipulated DLI. Lymphocytes were liberated from 9.4 cm of tumor and expanded for 14 days with anti-CD3/CD28-coated magnetic beads (3:1 bead-to-total nucleated cell ratio) and media containing IL-2 (100 or 1000 IU/mL). The cell products from the two culture conditions were similar. The process yielded 42.5 ϫ 10 6 cells, 33% expressing CD3, and generated 14.7 ϫ 10 9 TDL, 85% expressing CD3 (a 3.1-log T cell expansion). There was no tumor contamination of the T cell product by immunohistochemistry. Chimerism analysis revealed the TDL to be of donor origin. Flow cytometry showed an increase in the CD4/CD8 ratio from 1.3 to 1.9 after expansion. 76% of CD8 and 31% of CD4 cells secrete IFN-␥, and none secretes IL-2, IL-4 or IL-10. 76% of CD8 and 57% of CD4 cells expressed CXCR3. Three infusions of TDL were given in a dose-escalating manner (5, 25 and 100 ϫ 10 6 CD3 ϩ cells/kg). Two additional infusions were given in conjunction with low-dose IL-2, the second of which was preceded by one cycle of paclitaxel and trastuzumab cytoreductive therapy. No infusion-related or delayed toxicities were observed. The patient had no evidence of GVHD, even after the highest dose of 10 8 allogeneic T cells. Evaluation of the remaining thoracic lesion demonstrated progressive disease after the first two TDL infusions, transient disease stability after the third and fourth infusions, and at present, the patient has stable disease one month after the fifth infusion. This is the first clinical report of the application of TDL and represents a novel approach for adoptive immunotherapy in the setting of alloHSCT.
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